McMillan Shakespeare Ltd

MMS: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|.%LOCK|&SLOCK|bSxLj&P

McMillan Shakespeare Earnings: Executing Well but Fighting Margin Pressure

McMillan Shakespeare's first-half fiscal 2026 NPAT before impact of acquisitions and divestment-related items was flat at AUD 50 million. Revenue was up 11% while EBITDA grew 5%. Dividend payouts reduced to 85% of UNPATA from 100%, though the firm declared a AUD 10 million buyback. Shares fell 5%.

Sponsor Center